Toronto, ON – December 10, 2025 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is excited to announce that it has completed release testing of its first Australian-made batch of LaNeo™ MDMA 40mg capsules.
“PharmAla is pleased to have completed this first batch of material of Australian-made materials in partnership with our colleagues at Cortexa. This material will continue to drive progress in the Australian market, as well as our ongoing operations globally,” said Farnoud Kazemzadeh, COO, PharmAla Biotech. “However, we are all the more excited to move forward into a very active production schedule for 2026 – including the development and release of our 20mg capsules, and the manufacture and encapsulation of our first run of ALA-002 capsules.”
Delivery to Orygen
PharmAla is furthermore pleased to announce that it has completed its first delivery of its Australian-made product to the Orygen Institute. The shipment represents the second such shipment made by PharmAla to support Orygen’s Phase 3 Trial examining social anxiety in autistic youth.
This shipment represents the final shipment, and concludes PharmAla’s contract with Orygen.